Program
radiprodil
Also written as “Radiprodil”, “RGH-896” and “Radiprodil with Carbamazepine”.
Its studies are mostly in Tuberous Sclerosis · Neurodevelopmental Disorders · Spasms, Infantile · Pain, led by 3 companies.
Drug pageRadiprodil: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GRIN Therapeutics | 75 open or running | phase 3since Oct 31, 2025 | Feb 22, 2023 | Nov 2026phase 1 · NCT05818943 |
| UCBits history only | 20 open or running | phase 2since Jul 8, 2016 | Jan 4, 2016 | none ahead |
| AbbVieits history only | 10 open or running | phase 2since Feb 5, 2009 | Feb 5, 2009 | none ahead |
Also a collaborator on its studies: Angelini Pharma, Avance Clinical Pty, PRA Health Sciences and Gedeon Richter.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GRIN Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 22, 2023First study: phase 1 study in GRIN-related DisordersFirst studyNCT05818943 · 24 enrolled · United States, Australia, Canada and more
- Apr 23, 2024Phase 2 study in Tuberous SclerosisNCT06392009 · 30 enrolled · Australia, Belgium, Canada and more
- Apr 11, 20252 phase 1 studies in Tuberous SclerosisNCT06975605, NCT06965881
- Oct 31, 2025Phase 3 study in GRIN-related Neurodevelopmental DisorderNCT07224581 · 100 planned · United States, Australia, Belgium and more
- Feb 26, 2026Phase 1 study in Hepatic ImpairmentNCT07457229 · 40 planned · United States
- Nov 5, 2026Phase 1 study in GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-FunctionNCT07941206 · 27 planned
Ahead
- Nov 2026Primary completion: phase 1 study in GRIN-related DisordersNCT05818943
- May 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07457229
- May 2027Primary completion: phase 3 study in GRIN-related Neurodevelopmental DisorderNCT07224581
- Oct 2027Primary completion: phase 1 study in GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-FunctionNCT07941206
TargetBeta
“Glutamate NMDA receptor; GRIN1/GRIN2B antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esketaminerule | Johnson & Johnson | phase 4 | 51 |
| Memantinerule | AbbVie | phase 4 | 29 |
Studies
All 7 GRIN Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07941206GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function | 1 | Not yet recruiting | Oct 2027 | 27 |
| NCT07457229Hepatic Impairment · United States | 1 | Recruiting | May 2027 | 40 |
| NCT07224581GRIN-related Neurodevelopmental Disorder · United States, Australia, Belgium and more | 3 | Recruiting | May 2027 | 100 |
| NCT06975605Tuberous Sclerosis · Australia | 1 | Completed | Jul 10, 2025 | 18 |
| NCT06965881Tuberous Sclerosis · Australia | 1 | Terminated | Jul 8, 2025 | 30 |
| NCT06392009Tuberous Sclerosis · Australia, Belgium, Canada and more | 2 | Active, not recruiting | Jun 2026 | 30 |
| NCT05818943GRIN-related Disorders · United States, Australia, Canada and more | 1 | Active, not recruiting | Nov 2026 | 24 |
How it is read
Names in the registry
- “Radiprodil”, 6 entries
- “RGH-896”, 3 entries
- “Radiprodil with Carbamazepine”, 1 entry
- “Radiprodil with Itraconazole”, 1 entry
- “Radiprodil + co-administered drugs”, 1 entry
Conditions, from the studies’ own filings
- Tuberous Sclerosis, 3 studies
- Neurodevelopmental Disorders, 2 studies
- Spasms, Infantile, 1 study
- Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.